Treatment options for children with hemophilia A have expanded with the FDA approval of Bayer's Jivi antihemophilic factor ...

Bayer’s Jivi is a factor VIII replacement therapy that has been engineered with a compound that allows for less frequent dosing. It is now indicated for patients 7 years of age and older.

The approval in previously treated pediatric patients was based on data from the Alfa-PROTECT and PROTECT Kids studies.

The company said the discontinuation was due to several reasons,” Reuters news service reported, “including limited interest ...

The FDA has extended its approval of Jivi to cover the therapy's use in children with hemophilia A ages 7 years and older.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...